MNPR

Monopar Therapeutics Inc

Add to Watchlist

Advanced Chart

42.930

-0.47(-1.083%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

43.9342

Open

43.400

VWAP

Vol

560.00

Mkt Cap

265.40M

Low

42.910

Amount

EV/EBITDA(TTM)

Total Shares

17.48M

210.85M

EV/OCF(TTM)

P/S(TTM)

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.657

-76.12%

-0.513

-72.25%

-0.483

-3.33%

Estimates Revision

The market is revising No Change the revenue expectations for Monopar Therapeutics Inc. (MNPR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 2.31%.

EPS Estimates for FY2025

Revise Downward

-22.72%

In Past 3 Month

Stock Price

Go Up

+2.31%

In Past 3 Month

6 Analyst Rating

57.93% Upside

Wall Street analysts forecast MNPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNPR is 67.80 USD with a low forecast of 58.00 USD and a high forecast of 76.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

57.93% Upside

Current: 42.930

Low

58.00

Averages

67.80

High

76.00

57.93% Upside

Current: 42.930

Low

58.00

Averages

67.80

High

76.00

Cantor Fitzgerald

NULL -> Overweight

initiated

$74

2025-07-07

Reason

Cantor Fitzgerald

Price Target

$74

2025-07-07

initiated

NULL -> Overweight

Reason

Cantor Fitzgerald initiated coverage of Monopar Therapeutics with an Overweight rating and $74 price target.

Chardan

Keay Nakae

initiated

$60

2025-06-23

Reason

Chardan

Keay Nakae

Price Target

$60

2025-06-23

initiated

Reason

Chardan analyst Keay Nakae initiated coverage of Monopar Therapeutics with a Buy rating and $60 price target. The firm cites the potential of both the company's late stage clinical asset for Wilson disease and its early clinical stage radiopharmaceutical development pipeline for the Buy rating. Monopar's co-founder and Chief Executive Officer, Dr. Chandler Robinson, has a long history with the development of ALXN1840, the analyst tells investors in a research note.

Lucid Capital

initiated

$71

2025-06-05

Reason

Lucid Capital

Price Target

$71

2025-06-05

initiated

Reason

Lucid Capital initiated coverage of Monopar Therapeutics with a Buy rating and $71 price target. Monopar is developing a Phase 3 drug for Wilson disease and radiopharmaceuticals to directly target tumors with minimal systemic side effects, the analyst tells investors in a research note. The firm assumes ALXN-1840 could be approved in 2026 and launched in 2027 in the U.S.. In 2035, the drug could achieve about $220M in sales in the U.S., contends Lucid.

Jones Trading

Justin Walsh

Strong Buy

Hold

Downgrades

n/a

2025-04-02

Reason

Jones Trading

Justin Walsh

Price Target

n/a

2025-04-02

Downgrades

Strong Buy

Hold

Reason

HC Wainwright & Co.

Sean Lee

Strong Buy

Reiterates

$40

2025-04-01

Reason

HC Wainwright & Co.

Sean Lee

Price Target

$40

2025-04-01

Reiterates

Strong Buy

Reason

Piper Sandler

Biren Amin

Buy

Initiates

$76

2025-03-19

Reason

Piper Sandler

Biren Amin

Price Target

$76

2025-03-19

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Monopar Therapeutics Inc (MNPR.O) is -19.34, compared to its 5-year average forward P/E of -4.89. For a more detailed relative valuation and DCF analysis to assess Monopar Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.89

Current PE

-19.34

Overvalued PE

-0.34

Undervalued PE

-9.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00